Axsome Therapeutics Inc (AXSM)

07:56 AM

Axsome Therapeutics' SWOT analysis: strong pipeline, sales growth boost stock outlook - Investing.com

07:56 AM

Nov 20, 2024

Axsome Therapeutics (NASDAQ:AXSM) Rating Increased to Hold at StockNews.com - MarketBeat

Nov 20, 2024

Nov 20, 2024

Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up - MSN

Nov 20, 2024

Nov 20, 2024

Royce & Associates LP Has $2.02 Million Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Nov 20, 2024

Nov 19, 2024

First Turn Management LLC Trims Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Nov 19, 2024

Nov 17, 2024

Is It Too Late to Buy Viking Therapeutics Stock? - The Motley Fool

Nov 17, 2024

Nov 15, 2024

FY2024 EPS Estimates for AXSM Increased by Leerink Partnrs - MarketBeat

Nov 15, 2024

Nov 14, 2024

Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript - AOL

Nov 14, 2024

Nov 14, 2024

Axsome Therapeutics Inc (AXSM) Quarterly 10-Q Report - Quartzy

Nov 14, 2024

Nov 14, 2024

Axsome Advances Sleep Disorder Pipeline as Sunosi Prescriptions Increase in Q3 - Sleep Review

Nov 14, 2024

Nov 14, 2024

Equities Analysts Offer Predictions for AXSM FY2027 Earnings - MarketBeat

Nov 14, 2024

Nov 14, 2024

William Blair Issues Pessimistic Outlook for AXSM Earnings - MarketBeat

Nov 14, 2024

Nov 13, 2024

Axsome stock price target increased, rating held on strong sales - Investing.com

Nov 13, 2024

Nov 13, 2024

Axsome stock price target increased, rating held on strong sales By Investing.com - Investing.com UK

Nov 13, 2024

Nov 13, 2024

Axsome Therapeutics stock hits 52-week high at $98.61 By Investing.com - Investing.com Nigeria

Nov 13, 2024

Nov 13, 2024

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

Nov 13, 2024

Robert W. Baird Raises Axsome Therapeutics (NASDAQ:AXSM) Price Target to $116.00 - MarketBeat

Nov 13, 2024

Nov 13, 2024

Earnings call: Axsome Therapeutics reports record quarterly revenue By Investing.com - Investing.com Australia

Nov 13, 2024

Nov 13, 2024

Versor Investments LP Acquires New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Nov 13, 2024

Nov 12, 2024

Axsome Therapeutics’ Strong Q3 Growth Amidst Strategic Expansions - TipRanks

Nov 12, 2024

Nov 12, 2024

Axsome: Q3 Earnings Snapshot - Houston Chronicle

Nov 12, 2024

Nov 12, 2024

Earnings call: Axsome Therapeutics reports record quarterly revenue - Investing.com

Nov 12, 2024

Nov 12, 2024

Axsome Therapeutics stock hits 52-week high at $98.61 - Investing.com India

Nov 12, 2024

Nov 12, 2024

Axsome shares rise as Guggenheim lifts target to $135 By Investing.com - Investing.com UK

Nov 12, 2024

Nov 12, 2024

Axsome Therapeutics Q3 Earnings: Stay For Near Term Catalysts, Then Sell (AXSM) - Seeking Alpha

Nov 12, 2024

Nov 12, 2024

Axsome Therapeutics (NASDAQ:AXSM) Reaches New 52-Week HighShould You Buy? - MarketBeat

Nov 12, 2024

Nov 12, 2024

A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics - Benzinga

Nov 12, 2024

Nov 12, 2024

Axsome Therapeutics Inc earnings beat by $0.04, revenue topped estimates - Investing.com

Nov 12, 2024

Nov 12, 2024

Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 12, 2024

Nov 12, 2024

Axsome Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024

Nov 12, 2024

Axsome Therapeutics' (AXSM) Buy Rating Reiterated at Needham & Company LLC - MarketBeat

Nov 12, 2024

Nov 12, 2024

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 12, 2024

Nov 12, 2024

Truist maintains buy on Axsome with $150 target on strong Auvelity sales - Investing.com UK

Nov 12, 2024

Nov 10, 2024

(AXSM) Proactive Strategies - Stock Traders Daily

Nov 10, 2024

Nov 10, 2024

Privium Fund Management B.V. Grows Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Nov 10, 2024

Nov 09, 2024

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Position Decreased by Lindbrook Capital LLC - MarketBeat

Nov 09, 2024

Nov 08, 2024

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 - GlobeNewswire

Nov 08, 2024

Nov 08, 2024

Axsome Therapeutics to Present Breakthrough CNS Data Across 3 Major Disorders at NEI 2024 | AXSM Stock News - StockTitan

Nov 08, 2024

Nov 05, 2024

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

Nov 05, 2024

Nov 05, 2024

Axsome Therapeutics (AXSM) to Release Earnings on Tuesday - MarketBeat

Nov 05, 2024

Nov 05, 2024

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Position Trimmed by abrdn plc - MarketBeat

Nov 05, 2024

Nov 04, 2024

Assenagon Asset Management S.A. Lowers Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Nov 04, 2024

Nov 01, 2024

Analysts Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) Target Price at $124.64 - MarketBeat

Nov 01, 2024

Oct 31, 2024

(AXSM) Trading Advice - Stock Traders Daily

Oct 31, 2024

Oct 30, 2024

Upcoming Opportunities in Hypersomnia Therapeutics Market: - openPR

Oct 30, 2024

Oct 29, 2024

Axsome Therapeutics' (NASDAQ:AXSM) investors will be pleased with their impressive 257% return over the last five years - Simply Wall St

Oct 29, 2024

Oct 29, 2024

Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail

Oct 29, 2024

Oct 29, 2024

Major Depressive Disorder Market Expected to Experience Major - openPR

Oct 29, 2024

Oct 29, 2024

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 - The Manila Times

Oct 29, 2024